BIOTRON LIMITED - Announcements

Market Cap $18.04M Add to my watchlist

Healthcare Biotechnology

Biotron Limited is an Australia-based biotechnology company. The Company is primarily... Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

BIT	Appendix 3B		02/11/18	994.12KB	Share
BIT	Response to ASX aware letter	PRICE SENSITIVE	30/10/18	614.87KB	Share
BIT	Option Expiry Notice		29/10/18	538.62KB	Share
BIT	Appendix 3B		29/10/18	994.35KB	Share
BIT	Change of Director's Interest Notice		25/10/18	679.07KB	Share
BIT	Appendix 3B		25/10/18	994.29KB	Share
BIT	Presentation to Investors		25/10/18	5.67MB	Share
BIT	Appendix 3B		24/10/18	993.84KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/10/18	89.58KB	Share
BIT	Appendix 3B		23/10/18	994.37KB	Share
BIT	Appointment of a Director and Appendix 3X		23/10/18	31KB	Share
BIT	Appendix 3B		22/10/18	994.47KB	Share
BIT	Appendix 3B		18/10/18	993.84KB	Share
BIT	Appendix 3B		18/10/18	136.05KB	Share
BIT	Annual Report and Notice of AGM		18/10/18	7.46MB	Share
BIT	Biotron Secures $4.7 Million Underwriting Agreement	PRICE SENSITIVE	17/10/18	34.77KB	Share
BIT	$1.07 million R&D Tax Incentive Received	PRICE SENSITIVE	15/10/18	41.34KB	Share
BIT	Appendix 3B		11/10/18	418.11KB	Share
BIT	Letter to Shareholders		09/10/18	159.08KB	Share
BIT	Significant Immunological Outcomes in BIT225 HIV-1 Trial	PRICE SENSITIVE	28/09/18	406.97KB	Share
BIT	Appendix 4G and Corporate Governance Statement		29/08/18	727.19KB	Share
BIT	Full Year Statutory Accounts	PRICE SENSITIVE	29/08/18	2.02MB	Share
BIT	Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial	PRICE SENSITIVE	07/08/18	382.37KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	11/07/18	686.82KB	Share
BIT	Appendix 3B		10/07/18	902.9KB	Share
BIT	Change of Director's Interest Notice		14/06/18	690.75KB	Share
BIT	New Issue Announcement		14/06/18	1022.92KB	Share
BIT	New Issue Oversubscribed		12/06/18	289.17KB	Share
BIT	Appendix 3B		28/05/18	824.73KB	Share
BIT	Appendix 3B		16/05/18	824.75KB	Share
BIT	Letter to Eligible and Ineligible Shareholders		11/05/18	536.44KB	Share
BIT	Response to ASX Appendix 4C Query	PRICE SENSITIVE	10/05/18	986.36KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	10/05/18	630.61KB	Share
BIT	Prospectus	PRICE SENSITIVE	10/05/18	975.11KB	Share
BIT	Letter to Option Holders		10/05/18	549.88KB	Share
BIT	Appendix 3B		10/05/18	909.72KB	Share
BIT	Renounceable Rights Issue	PRICE SENSITIVE	10/05/18	5.54MB	Share
BIT	Trading Halt Request		08/05/18	320.51KB	Share
BIT	Trading Halt	PRICE SENSITIVE	08/05/18	67.26KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/18	686.08KB	Share
BIT	Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial	PRICE SENSITIVE	06/04/18	456.15KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/18	322.6KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	16/01/18	87.35KB	Share
BIT	Biotron Presents to Biotech Showcase 2018		10/01/18	1.53MB	Share
BIT	Appendix 3B		08/12/17	99.29KB	Share
BIT	Results of Meeting		20/11/17	38.8KB	Share
BIT	AGM Presentation		20/11/17	1.58MB	Share
BIT	Resignation of a Director		20/11/17	35.65KB	Share
BIT	Biotron Compounds Demonstrate Activity Against HBV	PRICE SENSITIVE	15/11/17	45.29KB	Share
BIT	$1.6 Million R&D Tax Incentive Received	PRICE SENSITIVE	01/11/17	39.7KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	26/10/17	179.5KB	Share
BIT	Annual Report and Notice of AGM/Proxy Form		18/10/17	2.05MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	13/10/17	162.75KB	Share
BIT	Presentation to Investors		06/10/17	2.98MB	Share
BIT	Full Year Statutory Accounts	PRICE SENSITIVE	28/08/17	585.8KB	Share
BIT	Appendix 4G and Corporate Governance Statement		28/08/17	201.92KB	Share
BIT	BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	27/07/17	36.52KB	Share
BIT	Appendix 3B		19/07/17	99.3KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	13/07/17	87.48KB	Share
BIT	Change of Director's Interest Notice		05/07/17	80.3KB	Share
BIT	Change of Director's Interest Notices		28/06/17	105.95KB	Share
BIT	Change of Director's Interest Notice		27/06/17	80.14KB	Share
BIT	New Issue Oversubscribed		23/06/17	31.25KB	Share
BIT	Change of Director's Interest Notice		22/06/17	80.02KB	Share
BIT	Change of Director's Interest Notice		19/06/17	45.35KB	Share
BIT	BIT225 Phase 2 HIV-1 Clinical Trial Update	PRICE SENSITIVE	15/06/17	45.74KB	Share
BIT	Advisor appointed to advance commercialisation in China		09/06/17	36.26KB	Share
BIT	Prospectus	PRICE SENSITIVE	25/05/17	170.89KB	Share
BIT	Renounceable Issue	PRICE SENSITIVE	25/05/17	2.02MB	Share
BIT	Appendix 3B		25/05/17	130.14KB	Share
BIT	The Need for Drugs Targeting HIV-1 in Macophages		01/05/17	64.38KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	20/04/17	87.41KB	Share
BIT	Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial	PRICE SENSITIVE	11/04/17	40.14KB	Share
BIT	Letter to Shareholders		27/02/17	231.2KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/17	256.06KB	Share
BIT	$1.6 Million R&D Tax Rebate Received	PRICE SENSITIVE	13/02/17	32.75KB	Share
BIT	Commencement of BIT225 Phase 2 HIV-1 Clinical Trial	PRICE SENSITIVE	13/02/17	41.94KB	Share
BIT	BIT225 Accelerates HIV-1 Virus Reduction	PRICE SENSITIVE	06/02/17	36.23KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	16/01/17	82.15KB	Share
BIT	Corrected Presentation to Biotech Showcase 2017		13/01/17	3.6MB	Share
BIT	Biotron Presents at Biotech Showcase 2017		13/01/17	3.47MB	Share
BIT	Results of Meeting		22/11/16	31.86KB	Share
BIT	AGM Presentation		22/11/16	1.66MB	Share
BIT	Annual report and Notice of Annual General Meeting-BIT.AX		17/10/16	894.71KB	Share
BIT	Appendix 4C - quarterly-BIT.AX	PRICE SENSITIVE	17/10/16	82.17KB	Share
BIT	Change of Director's Interest Notice-BIT.AX		05/10/16	41.02KB	Share
BIT	Appendix 3B-BIT.AX		05/10/16	111.3KB	Share
BIT	Clarification Statement-BIT.AX		05/09/16	43.93KB	Share
BIT	Option Expiry Notice-BIT.AX		02/09/16	106.54KB	Share
BIT	Zika Virus Program Update-BIT.AX	PRICE SENSITIVE	22/08/16	79.6KB	Share
BIT	Full Year Statutory Accounts-BIT.AX	PRICE SENSITIVE	05/08/16	428.34KB	Share
BIT	Appendix 4G and Corporate Governance Statement-BIT.AX		05/08/16	239.8KB	Share
BIT	Appendix 3B-BIT.AX		15/07/16	59.08KB	Share
BIT	Appendix 4C - quarterly-BIT.AX	PRICE SENSITIVE	08/07/16	22.67KB	Share
BIT	Appendix 3B-BIT.AX		07/07/16	59.09KB	Share
BIT	Biotron compounds demonstrate activity against Zika virus-BIT.AX	PRICE SENSITIVE	23/05/16	98.76KB	Share
BIT	Presentation at Biotech Invest 2016-BIT.AX		04/05/16	1.12MB	Share
BIT	$1.5 Million R&D Tax Rebate-BIT.AX	PRICE SENSITIVE	20/04/16	34.13KB	Share
BIT	Appendix 4C - quarterly-BIT.AX	PRICE SENSITIVE	20/04/16	22.69KB	Share
BIT	Letter to Shareholders-BIT.AX		12/04/16	239.67KB	Share

BIT Appendix 3B
02/11/18		994.12KB	Share
BIT Response to ASX aware letter
30/10/18	PRICE SENSITIVE	614.87KB	Share
BIT Option Expiry Notice
29/10/18		538.62KB	Share
BIT Appendix 3B
29/10/18		994.35KB	Share
BIT Change of Director's Interest Notice
25/10/18		679.07KB	Share
BIT Appendix 3B
25/10/18		994.29KB	Share
BIT Presentation to Investors
25/10/18		5.67MB	Share
BIT Appendix 3B
24/10/18		993.84KB	Share
BIT Appendix 4C - quarterly
24/10/18	PRICE SENSITIVE	89.58KB	Share
BIT Appendix 3B
23/10/18		994.37KB	Share
BIT Appointment of a Director and Appendix 3X
23/10/18		31KB	Share
BIT Appendix 3B
22/10/18		994.47KB	Share
BIT Appendix 3B
18/10/18		993.84KB	Share
BIT Appendix 3B
18/10/18		136.05KB	Share
BIT Annual Report and Notice of AGM
18/10/18		7.46MB	Share
BIT Biotron Secures $4.7 Million Underwriting Agreement
17/10/18	PRICE SENSITIVE	34.77KB	Share
BIT $1.07 million R&D Tax Incentive Received
15/10/18	PRICE SENSITIVE	41.34KB	Share
BIT Appendix 3B
11/10/18		418.11KB	Share
BIT Letter to Shareholders
09/10/18		159.08KB	Share
BIT Significant Immunological Outcomes in BIT225 HIV-1 Trial
28/09/18	PRICE SENSITIVE	406.97KB	Share
BIT Appendix 4G and Corporate Governance Statement
29/08/18		727.19KB	Share
BIT Full Year Statutory Accounts
29/08/18	PRICE SENSITIVE	2.02MB	Share
BIT Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
07/08/18	PRICE SENSITIVE	382.37KB	Share
BIT Appendix 4C - quarterly
11/07/18	PRICE SENSITIVE	686.82KB	Share
BIT Appendix 3B
10/07/18		902.9KB	Share
BIT Change of Director's Interest Notice
14/06/18		690.75KB	Share
BIT New Issue Announcement
14/06/18		1022.92KB	Share
BIT New Issue Oversubscribed
12/06/18		289.17KB	Share
BIT Appendix 3B
28/05/18		824.73KB	Share
BIT Appendix 3B
16/05/18		824.75KB	Share
BIT Letter to Eligible and Ineligible Shareholders
11/05/18		536.44KB	Share
BIT Response to ASX Appendix 4C Query
10/05/18	PRICE SENSITIVE	986.36KB	Share
BIT Response to ASX Price Query
10/05/18	PRICE SENSITIVE	630.61KB	Share
BIT Prospectus
10/05/18	PRICE SENSITIVE	975.11KB	Share
BIT Letter to Option Holders
10/05/18		549.88KB	Share
BIT Appendix 3B
10/05/18		909.72KB	Share
BIT Renounceable Rights Issue
10/05/18	PRICE SENSITIVE	5.54MB	Share
BIT Trading Halt Request
08/05/18		320.51KB	Share
BIT Trading Halt
08/05/18	PRICE SENSITIVE	67.26KB	Share
BIT Appendix 4C - quarterly
24/04/18	PRICE SENSITIVE	686.08KB	Share
BIT Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
06/04/18	PRICE SENSITIVE	456.15KB	Share
BIT Half Yearly Report and Accounts
23/02/18	PRICE SENSITIVE	322.6KB	Share
BIT Appendix 4C - quarterly
16/01/18	PRICE SENSITIVE	87.35KB	Share
BIT Biotron Presents to Biotech Showcase 2018
10/01/18		1.53MB	Share
BIT Appendix 3B
08/12/17		99.29KB	Share
BIT Results of Meeting
20/11/17		38.8KB	Share
BIT AGM Presentation
20/11/17		1.58MB	Share
BIT Resignation of a Director
20/11/17		35.65KB	Share
BIT Biotron Compounds Demonstrate Activity Against HBV
15/11/17	PRICE SENSITIVE	45.29KB	Share
BIT $1.6 Million R&D Tax Incentive Received
01/11/17	PRICE SENSITIVE	39.7KB	Share
BIT Response to ASX Price Query
26/10/17	PRICE SENSITIVE	179.5KB	Share
BIT Annual Report and Notice of AGM/Proxy Form
18/10/17		2.05MB	Share
BIT Appendix 4C - quarterly
13/10/17	PRICE SENSITIVE	162.75KB	Share
BIT Presentation to Investors
06/10/17		2.98MB	Share
BIT Full Year Statutory Accounts
28/08/17	PRICE SENSITIVE	585.8KB	Share
BIT Appendix 4G and Corporate Governance Statement
28/08/17		201.92KB	Share
BIT BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
27/07/17	PRICE SENSITIVE	36.52KB	Share
BIT Appendix 3B
19/07/17		99.3KB	Share
BIT Appendix 4C - quarterly
13/07/17	PRICE SENSITIVE	87.48KB	Share
BIT Change of Director's Interest Notice
05/07/17		80.3KB	Share
BIT Change of Director's Interest Notices
28/06/17		105.95KB	Share
BIT Change of Director's Interest Notice
27/06/17		80.14KB	Share
BIT New Issue Oversubscribed
23/06/17		31.25KB	Share
BIT Change of Director's Interest Notice
22/06/17		80.02KB	Share
BIT Change of Director's Interest Notice
19/06/17		45.35KB	Share
BIT BIT225 Phase 2 HIV-1 Clinical Trial Update
15/06/17	PRICE SENSITIVE	45.74KB	Share
BIT Advisor appointed to advance commercialisation in China
09/06/17		36.26KB	Share
BIT Prospectus
25/05/17	PRICE SENSITIVE	170.89KB	Share
BIT Renounceable Issue
25/05/17	PRICE SENSITIVE	2.02MB	Share
BIT Appendix 3B
25/05/17		130.14KB	Share
BIT The Need for Drugs Targeting HIV-1 in Macophages
01/05/17		64.38KB	Share
BIT Appendix 4C - quarterly
20/04/17	PRICE SENSITIVE	87.41KB	Share
BIT Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
11/04/17	PRICE SENSITIVE	40.14KB	Share
BIT Letter to Shareholders
27/02/17		231.2KB	Share
BIT Half Yearly Report and Accounts
24/02/17	PRICE SENSITIVE	256.06KB	Share
BIT $1.6 Million R&D Tax Rebate Received
13/02/17	PRICE SENSITIVE	32.75KB	Share
BIT Commencement of BIT225 Phase 2 HIV-1 Clinical Trial
13/02/17	PRICE SENSITIVE	41.94KB	Share
BIT BIT225 Accelerates HIV-1 Virus Reduction
06/02/17	PRICE SENSITIVE	36.23KB	Share
BIT Appendix 4C - quarterly
16/01/17	PRICE SENSITIVE	82.15KB	Share
BIT Corrected Presentation to Biotech Showcase 2017
13/01/17		3.6MB	Share
BIT Biotron Presents at Biotech Showcase 2017
13/01/17		3.47MB	Share
BIT Results of Meeting
22/11/16		31.86KB	Share
BIT AGM Presentation
22/11/16		1.66MB	Share
BIT Annual report and Notice of Annual General Meeting-BIT.AX
17/10/16		894.71KB	Share
BIT Appendix 4C - quarterly-BIT.AX
17/10/16	PRICE SENSITIVE	82.17KB	Share
BIT Change of Director's Interest Notice-BIT.AX
05/10/16		41.02KB	Share
BIT Appendix 3B-BIT.AX
05/10/16		111.3KB	Share
BIT Clarification Statement-BIT.AX
05/09/16		43.93KB	Share
BIT Option Expiry Notice-BIT.AX
02/09/16		106.54KB	Share
BIT Zika Virus Program Update-BIT.AX
22/08/16	PRICE SENSITIVE	79.6KB	Share
BIT Full Year Statutory Accounts-BIT.AX
05/08/16	PRICE SENSITIVE	428.34KB	Share
BIT Appendix 4G and Corporate Governance Statement-BIT.AX
05/08/16		239.8KB	Share
BIT Appendix 3B-BIT.AX
15/07/16		59.08KB	Share
BIT Appendix 4C - quarterly-BIT.AX
08/07/16	PRICE SENSITIVE	22.67KB	Share
BIT Appendix 3B-BIT.AX
07/07/16		59.09KB	Share
BIT Biotron compounds demonstrate activity against Zika virus-BIT.AX
23/05/16	PRICE SENSITIVE	98.76KB	Share
BIT Presentation at Biotech Invest 2016-BIT.AX
04/05/16		1.12MB	Share
BIT $1.5 Million R&D Tax Rebate-BIT.AX
20/04/16	PRICE SENSITIVE	34.13KB	Share
BIT Appendix 4C - quarterly-BIT.AX
20/04/16	PRICE SENSITIVE	22.69KB	Share
BIT Letter to Shareholders-BIT.AX
12/04/16		239.67KB	Share

REFRESH

First 2 3 4 5

(20min delay)
Last 2.0¢		Change -0.001(4.76%)		Mkt cap ! $18.04M

Open	High	Low	Value	Volume
2.1¢	2.1¢	2.0¢	$12.00K	600.2K

Buyers (Bids)

No.	Vol.	Price($)
5	972631	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.1¢	199783	1

View Market Depth

No.	Vol.	Price($)
5	972631	0.019
10	2364942	0.018
6	738000	0.017
11	1456225	0.016
4	635000	0.015

Price($)	Vol.	No.
0.021	199783	1
0.022	41868	2
0.023	506413	1
0.024	222185	3
0.025	600000	3

Last trade - 14.33pm 01/11/2024 (20 minute delay)


Last 2.0¢		Change -0.001 ( 4.76 %)
Open	High	Low	Volume
2.0¢	2.0¢	2.0¢	199442
Last updated 14.33pm 01/11/2024 ?

BIT (ASX) Chart

BIOTRON LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available